The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | GRIFFIN: subgroup analysis of patients with multiple myeloma with high-risk cytogenetics
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, outlines the results of a subgroup analysis of the GRIFFIN trial (NCT02874742) investigating the efficacy of the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (D-RVd) in patients with multiple myeloma with high-risk cytogenetics. Dr Voorhees explains that adding 1q21 gain to the high-risk markers defined by IMWG criteria increases the study’s power which allows determining whether daratumumab provides a significant benefit to this patient population. After incorporating patients with 1q21 gain to the subgroup analysis, the study reported a trend towards an improved progression-free survival (PFS) for high-risk patients treated with D-RVd compared to RVd alone. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Janssen: Other: Advisory Board; Novartis: Consultancy; Oncopeptides: Consultancy, Honoraria; TeneoBio: Other: Advisory Board; Adaptive Biotechnologies: Other: Advisory Board; BMS: Other: Advisory Board; GSK: Honoraria.
